Neuromyelitis optica: Clinical features, immunopathogenesis and treatment

Clinical and Experimental Immunology

Volumn 176, Issue 2, 2014, Pages 149-164

  Jarius, S ^a   Wildemann, B ^a   Paul, F ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aquaporin 4 antibodies (AQP4); Devic syndrome; Diagnosis; Neuromyelitis optica; NMO IgG; Pathogenesis; Pathophysiology; Treatment

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ARTICLE; AUTOIMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DISEASE COURSE; EVOKED VISUAL RESPONSE; GRANULOCYTE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

AQUAPORIN-4 ANTIBODIES (AQP4); DEVIC SYNDROME; DIAGNOSIS; NEUROMYELITIS OPTICA; NMO-IGG; PATHOGENESIS; PATHOPHYSIOLOGY; TREATMENT;

ANTIBODIES, MONOCLONAL; AQUAPORIN 4; AUTOANTIBODIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; NEUROMYELITIS OPTICA; PROGNOSIS;

EID: 84897929097     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12271     Document Type: Article

References (291)

1. Jarius S, Ruprecht K, Wildemann B etal. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012; 9:14.
2. Wildemann B, Jarius S, Paul F. [Neuromyelitis optica]. Nervenarzt 2013; 84:436-441.
3. Jarius S, Wildemann B. [Neuromyelitis optica]. Nervenarzt 2007; 78:1365-1377.
4. Trebst C, Berthele A, Jarius S etal. [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group]. Nervenarzt 2011; 82:768-777.
5. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202:473-477.
6. Lennon VA, Wingerchuk DM, Kryzer TJ etal. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106-2112.
7. Jarius S, Franciotta D, Bergamaschi R etal. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68:1076-1077.
8. Paul F, Jarius S, Aktas O etal. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLOS Med 2007; 4:e133.
9. Jarius S, Probst C, Borowski K etal. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010; 291:52-56.
10. Jarius S, Franciotta D, Paul F etal. Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci 2012; 320:32-37.
11. Waters P, Jarius S, Littleton E etal. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65:913-919.
12. Lucchinetti CF, Mandler RN, McGavern D etal. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125:1450-1461.
13. Wildemann B, Jarius S. The expanding range of autoimmune disorders of the nervous system. Lancet Neurol 2013; 12:22-24.
14. Wildemann B, Bien CG. [Immune-mediated encephalomyelitis]. Nervenarzt 2013; 84:435.
15. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6:805-815.
16. Lennon VA. Changing concepts in CNS demyelinating disorders: autoimmune water channelopathies. In: Program and abstracts of the American Academy of Neurology 58th Annual Meeting; 1-8 April 2006; San Diego, CA, USA. Plenary session. 2006.
17. Matsushita T, Isobe N, Matsuoka T etal. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler 2009; 15:834-847.
18. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation 2013; 10:8.
19. Jarius S, Wildemann B. 'Noteomielite' accompanied by acute amaurosis (1844). An early case of neuromyelitis optica. J Neurol Sci 2012; 313:182-184.
20. Jarius S, Wildemann B. On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol 2013; 260:100-104.
21. Jarius S, Wildemann B. An early British case of neuromyelitis optica (1850). BMJ 2012; 345:e6430.
22. Jarius S, Wildemann B. An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult Scler 2011; 17:1384-1386.
23. Jarius S, Wildemann B. The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol 2012; 259:1354-1357.
24. Jarius S, Wildemann B. 'Spinal amaurosis' (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. J Neurol 2014; 261:400-404.
25. Devic E. [Myélite aiguë dorso-lombaire avec névrite optique - Autopsie.Congrès français de médecine (Premiere Session; Lyon, 1894; Procès-verbaux, mémoires et discussions; Publiés par M le Dr L Bard)]. Lyon: Asselin et Houzeau, Louis Savy, 1895:434-439.
26. Gault F. [De la neuromyélite optique aiguë. Thése.Faculté de Médecine et de Pharmacie]. Lyon, 1894:102.
27. Asgari N, Khorooshi R, Lillevang ST, Owens T. Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid. J Neuroimmunol 2013; 254:76-82.
28. Jacob A, Panicker J, Lythgoe D etal. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 2013; 260:2134-2137.
29. Bizzoco E, Lolli F, Repice AM etal. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009; 256:1891-1898.
30. Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF etal. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol 2012; 259:1929-1935.
31. Cossburn M, Tackley G, Baker K etal. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 2012; 19:655-659.
32. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012; 69:1176-1180.
33. Yamakawa K, Kuroda H, Fujihara K etal. Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan. Neurology 2000; 55:318-320.
34. Nouh A, Ali AM, Wichter MD, Messer E. One of the oldest patients with neuromyelitis optica in the literature. Mult Scler 2013; 19:256.
35. Huppke P, Bluthner M, Bauer O etal. Neuromyelitis optica and NMO-IgG in European pediatric patients. Neurology 2010; 75:1740-1744.
36. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107-1114.
37. Lim BC, Hwang H, Kim KJ etal. Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica. Mult Scler 2011; 17:67-73.
38. Krupp LB, Tardieu M, Amato MP etal. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19:1261-1267.
39. Banwell B, Tenembaum S, Lennon VA etal. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70:344-352.
40. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci 2009; 286:18-23.
41. Matiello M, Kim HJ, Kim W etal. Familial neuromyelitis optica. Neurology 2010; 75:310-315.
42. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007; 68:603-605.
43. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452.
44. Ghezzi A, Bergamaschi R, Martinelli V etal. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica. J Neurol 2004; 251:47-52.
45. Collongues N, Cabre P, Marignier R etal. A benign form of neuromyelitis optica: does it exist? Arch Neurol 2011; 68:918-924.
46. Iorio R, Lucchinetti CF, Lennon VA etal. Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol 2013; 11:240-245.
47. Popescu BF, Lennon VA, Parisi JE etal. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011; 76:1229-1237.
48. Kim SM, Kim JS, Heo YE, Yang HR, Park KS. Cortical oscillopsia without nystagmus, an isolated symptom of neuromyelitis optica spectrum disorder with anti-aquaporin 4 antibody. Mult Scler 2012; 18:244-247.
49. Kim W, Kim SH, Lee SH, Li XF, Kim HJ. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler 2011; 17:1107-1112.
50. Iorio R, Lucchinetti CF, Lennon VA etal. Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. Neurology 2011; 77:1644-1646.
51. Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 2013; 23:661-683.
52. Nakano H, Tanaka M, Kinoshita M etal. Epileptic seizures in Japanese patients with multiple sclerosis and neuromyelitis optica. Epilepsy Res 2012; 104:175-180.
53. Magana SM, Matiello M, Pittock SJ etal. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72:712-717.
54. Takai Y, Misu T, Nakashima I etal. Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology 2012; 79:1826-1828.
55. Wang JY, Wang K, Chen XW etal. Meningoencephalitis as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler 2012; 19:639-643.
56. Jarius S, Lauda F, Wildemann B, Tumani H. Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica. J Neurol 2013; 260:663-664.
57. Vernant JC, Cabre P, Smadja D etal. Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology 1997; 48:58-64.
58. Schmidt F, Göktas Ö, Jarius S etal. Olfactory dysfunction in patients with neuromyelitis optica. Mult Scler Int 2013; 654501. doi:10.1155/2013/654501.
59. Kanamori Y, Nakashima I, Takai Y etal. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology 2011; 77:652-658.
60. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 2012; 69:1482-1487.
61. Blanc F, Zephir H, Lebrun C etal. Cognitive functions in neuromyelitis optica. Arch Neurol 2008; 65:84-88.
62. Blanc F, Noblet V, Jung B etal. White matter atrophy and cognitive dysfunctions in neuromyelitis optica. PLOS ONE 2012; 7:e33878.
63. Saji E, Arakawa M, Yanagawa K etal. Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 2013; 73:65-76.
64. Jarius S, Jacobi C, de Seze J etal. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 2011; 17:1067-1073.
65. Wandinger KP, Stangel M, Witte T etal. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum 2010; 62:1198-1200.
66. Zavada J, Nytrova P, Wandinger KP etal. Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatol Int 2013; 33:259-263.
67. Pittock SJ, Lennon VA, de Seze J etal. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65:78-83.
68. Jarius S, Paul F, Franciotta D etal. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 2012; 18:1135-1143.
69. Jarius S, Paul F, Martins da Silva A etal. Neuromyelitis optica and longitudinally extensive transverse myelitis following thymectomy for myasthenia gravis. Mult Scler 2007; 13:P534.
70. Kay CS, Scola RH, Lorenzoni PJ, Jarius S, Arruda WO, Werneck LC. NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci 2008; 275:148-150.
71. Leite MI, Coutinho E, Lana-Peixoto M etal. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 2012; 78:1601-1607.
72. Bergamaschi R, Jarius S, Robotti M, Pichiecchio A, Wildemann B, Meola G. Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol 2009; 256:2097-2099.
73. Jarius S, Jacob S, Waters P, Jacob A, Littleton E, Vincent A. Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. J Neurol Neurosurg Psychiatry 2008; 79:1084.
74. Jarius S, Paul F, Ruprecht K, Wildemann B. Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol 2012; 259:2743-2745.
75. Fragoso YD, Adoni T, Bichuetti DB etal. Neuromyelitis optica and pregnancy. J Neurol 2013; 260:2614-2619.
76. Kim W, Kim SH, Nakashima I etal. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 2012; 78:1264-1267.
77. Saadoun S, Waters P, Leite MI, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol 2013; 191:2999-3005.
78. Reuss R, Rommer PS, Bruck W etal. A woman with acute myelopathy in pregnancy: case outcome. BMJ 2009; 339:b4026.
79. Reuss R, Rommer PS, Brueck W, Jarius S, Bolz M, Zettl UK. Anti-AQP4 Ab might be relevant in pregnancy. BMJ 2010 Feb 8; online reply.
80. Deguchi S, Deguchi K, Sato K etal. HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica. Intern Med 2012; 51:2617-2620.
81. Di Filippo M, Franciotta D, Massa R etal. Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology 2012; 79:1182-1184.
82. Suzuki N, Takahashi T, Aoki M etal. Neuromyelitis optica preceded by hyperCKemia episode. Neurology 2010; 74:1543-1545.
83. Jeret JS, Suzuki N, Takahashi T, Fujihara K. Neuromyelitis optica preceded by hyperCKemia episode. Neurology 2010; 75:2253; author reply 4.
84. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485-1489.
85. Jarius S, Paul F, Franciotta D etal. Revised diagnostic criteria for neuromyelitis optica - incorporation of NMO-IgG status. Nat Clin Pract Neurol 2007; 3:E1.
86. Paty DW, Oger JJ, Kastrukoff LF etal. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38:180-185.
87. Jarius S, Aboul-Enein F, Waters P etal. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008; 131:3072-3080.
88. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6:383-392.
89. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012; 11:535-544.
90. Ratelade J, Verkman AS. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol 2012; 44:1519-1530.
91. Dellavance A, Alvarenga RR, Rodrigues SH, Kok F, de Souza AW, Andrade LE. Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases. Eur J Neurol 2012; 19:248-252.
92. Mader S, Lutterotti A, Di Pauli F etal. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLOS ONE 2010; 5:e10455.
93. McKeon A, Fryer JP, Apiwattanakul M etal. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009; 66:1134-1138.
94. Isobe N, Yonekawa T, Matsushita T etal. Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Mult Scler 2012; 18:1541-1551.
95. Jarius S, Paul F, Franciotta D etal. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008; 4:202-214.
96. Kim W, Lee JE, Li XF etal. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler 2012; 18:578-586.
97. Takahashi T, Fujihara K, Nakashima I etal. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130:1235-1243.
98. Chihara N, Aranami T, Sato W etal. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011; 108:3701-3706.
99. Jarius S, Frederikson J, Waters P etal. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010; 298:158-162.
100. Weinshenker BG, Wingerchuk DM, Vukusic S etal. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59:566-569.
101. Matiello M, Lennon VA, Jacob A etal. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70:2197-2200.
102. Akman-Demir G, Tuzun E, Waters P etal. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol 2011; 258:464-470.
103. Kitley J, Leite MI, Nakashima I etal. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135:1834-1849.
104. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009; 15:487-492.
105. Khatri BO, Kramer J, Dukic M, Palencia M, Verre W. Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apher 2012; 27:183-192.
106. Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 2013; 9:36-42.
107. Merle H, Olindo S, Jeannin S etal. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 2012; 130:858-862.
108. Watanabe S, Nakashima I, Misu T etal. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13:128-132.
109. Watanabe S, Nakashima I, Miyazawa I etal. Successful treatment of a hypothalamic lesion in neuromyelitis optica by plasma exchange. J Neurol 2007; 254:670-671.
110. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011; 17:1225-1230.
111. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64:1270-1272.
112. Jacob A, Weinshenker BG, Violich I etal. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65:1443-1448.
113. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011; 68:1412-1420.
114. Pellkofer HL, Krumbholz M, Berthele A etal. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76:1310-1315.
115. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2012; 23:827-851.
116. Ayzenberg I, Kleiter I, Schroder A etal. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013; 70:394-397.
117. Kieseier BC, Stuve O, Dehmel T etal. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. Arch Neurol 2013; 70:390-393.
118. Matiello M, Schaefer-Klein J, Sun D, Weinshenker BG. Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 2013; 70:1118-1125.
119. Misu T, Fujihara K, Kakita A etal. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007; 130:1224-1234.
120. Roemer SF, Parisi JE, Lennon VA etal. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130:1194-1205.
121. Sinclair C, Kirk J, Herron B, Fitzgerald U, McQuaid S. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol (Berl) 2007; 113:187-194.
122. Misu T, Hoftberger R, Fujihara K etal. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol (Berl) 2013; 125:815-827.
123. Hinson SR, Pittock SJ, Lucchinetti CF etal. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69:2221-2231.
124. Hinson SR, Romero MF, Popescu BF etal. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA 2012; 109:1245-1250.
125. Rossi A, Ratelade J, Papadopoulos MC, Bennett JL, Verkman AS. Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia 2012; 60:2027-2039.
126. Hinson SR, Roemer SF, Lucchinetti CF etal. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008; 205:2473-2481.
127. Melamud L, Fernandez JM, Rivarola V etal. Neuromyelitis optica immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin-4 expression and water permeability of the astrocyte plasma membrane. J Neurosci Res 2012; 90:1240-1248.
128. Vincent T, Saikali P, Cayrol R etal. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008; 181:5730-5737.
129. Ratelade J, Bennett JL, Verkman AS. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem 2011; 286:45156-45164.
130. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133:349-361.
131. Bennett JL, Lam C, Kalluri SR etal. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66:617-629.
132. Bradl M, Misu T, Takahashi T etal. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66:630-643.
133. Kinoshita M, Nakatsuji Y, Kimura T etal. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009; 386:623-627.
134. Kinoshita M, Nakatsuji Y, Kimura T etal. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 2010; 394:205-210.
135. Jarius S, Jacob S, Leite MI, Waters P, Vincent A. NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro. Mult Scler 2007; 13:P533.
136. Kalluri SR, Illes Z, Srivastava R etal. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 2010; 67:1201-1208.
137. Kuroda H, Fujihara K, Takano R etal. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 2013; 254:178-182.
138. Pittock SJ, Lennon VA, McKeon A etal. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12:554-562.
139. Paul F. Hope for a rare disease: eculizumab in neuromyelitis optica. Lancet Neurol 2013; 12:529-531.
140. Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 2009; 66:1164-1167.
141. Sabater L, Giralt A, Boronat A etal. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 2009; 215:31-35.
142. Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem 2012; 287:13829-13839.
143. Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 2011; 70:943-954.
144. Tradtrantip L, Zhang H, Saadoun S etal. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012; 71:314-322.
145. Tradtrantip L, Asavapanumas N, Verkman AS. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol 2013; 83:1268-1275.
146. Tradtrantip L, Ratelade J, Zhang H, Verkman AS. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 2013; 73:77-85.
147. Phuan PW, Anderson MO, Tradtrantip L etal. A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica-immunoglobulin G binding to aquaporin-4. J Biol Chem 2012; 287:36837-36844.
148. Tradtrantip L, Zhang H, Anderson MO etal. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J 2012; 26:2197-2208.
149. Saadoun S, Bridges LR, Verkman AS, Papadopoulos MC. Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions. Neuroreport 2012; 23:1044-1047.
150. Icoz S, Tuzun E, Kurtuncu M etal. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 2010; 120:71-75.
151. Uzawa A, Mori M, Ito M etal. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009; 256:2082-2084.
152. Wang H, Wang K, Zhong X etal. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol 2012; 32:1007-1011.
153. Vaknin-Dembinsky A, Brill L, Orpaz N, Abramsky O, Karussis D. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Mult Scler 2010; 16:1453-1457.
154. Quan C, Yu H, Qiao J etal. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. Mult Scler 2013; 19:289-298.
155. Korn T, Mitsdoerffer M, Croxford AL etal. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008; 105:18460-18465.
156. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009; 183:3170-3176.
157. Wang HH, Dai YQ, Qiu W etal. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 2011; 18:1313-1317.
158. Linhares UC, Schiavoni PB, Barros PO etal. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 2013; 33:179-189.
159. Arellano B, Hussain R, Zacharias T etal. Human aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with Neuromyelitis optica. Arch Neurol 2012; 69:1125-1131.
160. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U etal. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012; 72:53-64.
161. Quan C, Yu H, Qiao J etal. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. Mult Scler 2012; 19:289-298.
162. Wang H, Zhong X, Wang K etal. Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese - a case control study. J Neurol Sci 2012; 314:26-28.
163. Ishizu T, Osoegawa M, Mei FJ etal. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128:988-1002.
164. Bjerke T, Gaustadnes M, Nielsen S etal. Human blood eosinophils produce and secrete interleukin 4. Respir Med 1996; 90:271-277.
165. Jarius S, Paul F, Franciotta D etal. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures. J Neurol Sci 2011; 306:82-90.
166. Saadoun S, Waters P, MacDonald C etal. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol 2012; 71:323-333.
167. Jacob A, Saadoun S, Kitley J etal. Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence. Mult Scler 2012; 18:1801-1803.
168. Zhang H, Verkman AS. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 2013; 123:2306-2316.
169. Barnett MH, Prineas JW, Buckland ME, Parratt JD, Pollard JD. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012; 18:108-112.
170. Kleiter I, Hellwig K, Berthele A etal. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69:239-245.
171. Jacob A, Hutchinson M, Elsone L etal. Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012; 79:1065-1066.
172. Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC, Verkman AS. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol (Berl) 2012; 123:861-872.
173. Mitsdoerffer M, Lee Y, Jager A etal. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci USA 2010; 107:14292-14297.
174. Brum DG, Barreira AA, dos Santos AC etal. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler 2010; 16:21-29.
175. Zephir H, Fajardy I, Outteryck O etal. Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler 2009; 15:571-579.
176. Nelson PA, Khodadoust M, Prodhomme T etal. Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLOS ONE 2010; 5:e15050.
177. Kalluri SR, Rothhammer V, Staszewski O etal. Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLOS ONE 2011; 6:e16083.
178. Vaknin-Dembinsky A, Brill L, Kassis I etal. T-cell reactivity against AQP4 in neuromyelitis optica. Neurology 2012; 79:945-946.
179. Warabi Y, Yagi K, Hayashi H, Matsumoto Y. Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is up-regulated compared to multiple sclerosis. J Neurol Sci 2006; 249:145-152.
180. Matsuya N, Komori M, Nomura K etal. Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int Immunol 2011; 23:565-573.
181. Ren Z, Wang Y, Duan T etal. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol 2012; 189:4602-4611.
182. Jarius S, Wandinger KP, Platzer S, Wildemann B. Homology between Klebsiella pneumoniae and human aquaporin-4: no evidence for cross-reactivity in neuromyelitis optica. A study on 114 patients. J Neurol 2011; 258:929-931.
183. Sellner J, Hemmer B, Muhlau M. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun 2010; 34:371-379.
184. Menge T, Cree B, Saleh A etal. Neuromyelitis optica following human papillomavirus vaccination. Neurology 2012; 79:285-287.
185. Alberdi E, Sanchez-Gomez MV, Torre I etal. Activation of kainate receptors sensitizes oligodendrocytes to complement attack. J Neurosci 2006; 26:3220-3228.
186. Nicchia GP, Mastrototaro M, Rossi A etal. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009; 57:1363-1373.
187. Rossi A, Ratelade J, Papadopoulos MC, Bennett JL, Verkman AS. Consequences of NMO-IgG binding to aquaporin-4 in neuromyelitis optica. Proc Natl Acad Sci USA 2012; 109:E1511; author reply E2.
188. Jarius S, Franciotta D, Bergamaschi R, Wildemann B, Wandinger KP. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med 2010; 48:659-663.
189. Jiao Y, Fryer JP, Lennon VA etal. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013; 81:1197-1204.
190. Marignier R, Bernard-Valnet R, Giraudon P etal. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 2013; 80:2194-2200.
191. Waters PJ, McKeon A, Leite MI etal. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78:665-671; discussion 9.
192. Mori M, Hosoya M, Hiwasa T, Hayakawa S, Uzawa A, Kuwabara S. Detection of mumps virus RNA in cerebrospinal fluid of patients with neuromyelitis optica. Neurol Sci 2011; 32:795-799.
193. Koga M, Takahashi T, Kawai M, Fujihara K, Kanda T. A serological analysis of viral and bacterial infections associated with neuromyelitis optica. J Neurol Sci 2011; 300:19-22.
194. Mader S, Gredler V, Schanda K etal. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8:184.
195. Rostasy K, Mader S, Hennes E etal. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013; 19:1052-1059.
196. Kitley J, Woodhall M, Waters P etal. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79:1273-1277.
197. Mayer MC, Breithaupt C, Reindl M etal. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 2013; 191:3594-3604.
198. Jarius S, Wandinger KP, Borowski K, Stoecker W, Wildemann B. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 2012; 114:331-335.
199. Kruer MC, Koch TK, Bourdette DN etal. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology 2010; 74:1473-1475.
200. Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol 2002; 22:105-122.
201. Trebst C, Raab P, Voss EV etal. Longitudinal extensive transverse myelitis - it's not all neuromyelitis optica. Nat Rev Neurol 2011; 7:688-698.
202. Kitley JL, Leite MI, George JS, Palace JA. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler 2012; 18:271-285.
203. Andersson M, Alvarez-Cermeno J, Bernardi G etal. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994; 57:897-902.
204. Reiber H, Teut M, Pohl D, Rostasy KM, Hanefeld F. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult Scler 2009; 15:1466-1480.
205. Walsh MJ, Tourtellotte WW. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 1986; 163:41-53.
206. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998; 4:111-117.
207. Jarius S, Eichhorn P, Jacobi C, Wildemann B, Wick M, Voltz R. The intrathecal, polyspecific antiviral immune response: specific for MS or a general marker of CNS autoimmunity? J Neurol Sci 2009; 280:98-100.
208. Jarius S, Eichhorn P, Wildemann B, Wick M. Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands. Fluids Barriers CNS 2012 Jul 31; 9:14.
209. Jarius S, Franciotta D, Bergamaschi R etal. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 2008; 79:1134-1136.
210. Jarius S, Wildemann B. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link. Med Hypotheses 2013; 81:1090-1095.
211. Lepur D, Peterkovic V, Kalabric-Lepur N. Neuromyelitis optica with CSF examination mimicking bacterial meningomyelitis. Neurol Sci 2009; 30:51-54.
212. Jarius S, Warth A, Wandinger KP etal. Antibodies to aquaporin-4 in non-small cell lung cancer: a study on 50 patients. Neurol Sci 2010; 31:871-872.
213. Symmonds M, Nirmalananthan N, Taylor GP, Bridges LR, Schon F. Devastating aquaporin-4 and HTLV-1-associated necrotizing encephalopathy. J Neurol 2012; 259:2732-2735.
214. von Glehn F, Jarius S, Penalva de Oliveira AC etal. Aquaporin-4 antibodies are not related to HTLV-1 associated myelopathy. PLOS ONE 2012; 7:e39372.
215. Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2009; 72:2132-2133.
216. Jarius S, Franciotta D, Paul F etal. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010; 7:52.
217. Dujmovic I, Mader S, Schanda K etal. Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders. J Neuroimmunol 2011; 234:124-130.
218. Heerlein K, Jarius S, Jacobi C, Rohde S, Storch-Hagenlocher B, Wildemann B. Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. J Neurol Sci 2009; 276:184-186.
219. Kiyat-Atamer A, Ekizoglu E, Tuzun E etal. Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients. Eur J Neurol 2013; 20:781-787.
220. Lim YM, Pyun SY, Kang BH, Kim J, Kim KK. Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler 2013; 19:1216-1218.
221. Yonezu T, Ito S, Mori M etal. 'Bright spotty lesions' on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler 2013 Jul 4; epub ahead of print. doi:10.1177/1352458513495581.
222. Klawiter EC, Xu J, Naismith RT etal. Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler 2012; 18:1259-1268.
223. Naismith RT, Xu J, Klawiter EC etal. Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease. Neurology 2013; 80:2201-2209.
224. Ciccarelli O, Thomas D, De Vita E etal. Low myo-inositol indicating astrocytic damage in a case series of NMO. Ann Neurol 2013 Apr 3; epub ahead of print. doi:10.1002/ana.23909.
225. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63:390-396.
226. Matthews L, Marasco R, Jenkinson M etal. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013; 80:1330-1337.
227. Kim W, Kim SH, Huh SY, Kim HJ. Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int 2012; 2012:735486.
228. Sinnecker T, Dorr J, Pfueller CF etal. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 2012; 79:708-714.
229. Kister I, Herbert J, Zhou Y, Ge Y. Ultrahigh-field MR (7 T) imaging of brain lesions in neuromyelitis optica. Mult Scler Int 2013; 2013:398259.
230. Popescu BF, Parisi JE, Cabrera-Gomez JA etal. Absence of cortical demyelination in neuromyelitis optica. Neurology 2010; 75:2103-2109.
231. Calabrese M, Oh MS, Favaretto A etal. No MRI evidence of cortical lesions in neuromyelitis optica. Neurology 2012; 79:1671-1676.
232. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63:964-968.
233. Zhang L, Wu A, Zhang B etal. Comparison of deep gray matter lesions on magnetic resonance imaging among adults with acute disseminated encephalomyelitis, multiple sclerosis, and neuromyelitis optica. Mult Scler 2014 Jan 22; epub ahead of print. doi:10.1177/1352458513499420.
234. Chan KH, Tse CT, Chung CP etal. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol 2011; 68:1432-1439.
235. Makino T, Ito S, Mori M, Yonezu T, Ogawa Y, Kuwabara S. Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Mult Scler 2012; 19:308-315.
236. Kim W, Park MS, Lee SH etal. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010; 16:1229-1236.
237. Banker P, Sonni S, Kister I, Loh JP, Lui YW. Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler 2012; 18:1050-1053.
238. Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S. 'Cloud-like enhancement' is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009; 66:425-428.
239. Chanson JB, Lamy J, Rousseau F etal. White matter volume is decreased in the brain of patients with neuromyelitis optica. Eur J Neurol 2013; 20:361-367.
240. Sanchez-Catasus CA, Cabrera-Gomez J, Almaguer Melian W etal. Brain tissue volumes and perfusion change with the number of optic neuritis attacks in relapsing neuromyelitis optica: a voxel-based correlation study. PLOS ONE 2013; 8:e66271.
241. Rueda Lopes FC, Doring T, Martins C etal. The role of demyelination in neuromyelitis optica damage: diffusion-tensor MR imaging study. Radiology 2012; 263:235-242.
242. Liu Y, Duan Y, He Y etal. A tract-based diffusion study of cerebral white matter in neuromyelitis optica reveals widespread pathological alterations. Mult Scler 2012; 18:1013-1021.
243. Zhao DD, Zhou HY, Wu QZ etal. Diffusion tensor imaging characterization of occult brain damage in relapsing neuromyelitis optica using 3.0T magnetic resonance imaging techniques. Neuroimage 2012; 59:3173-3177.
244. Matsuoka T, Matsushita T, Osoegawa M etal. Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings. J Neurol Sci 2008; 266:115-125.
245. Ishizu T, Kira J, Osoegawa M etal. Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey. J Neurol Sci 2009; 280:22-28.
246. Pfueller CF, Paul F. Imaging the visual pathway in neuromyelitis optica. Mult Scler Int 2011; 2011:869814.
247. Brandt AU, Zimmermann H, Kaufhold F etal. Patterns of retinal damage facilitate differential diagnosis between Susac syndrome and MS. PLOS ONE 2012; 7:e38741.
248. Stricker S, Oberwahrenbrock T, Zimmermann H etal. Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1. PLOS ONE 2011; 6:e23024.
249. Zimmermann H, Freing A, Kaufhold F etal. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler 2013; 19:443-450.
250. Bock M, Brandt AU, Dorr J etal. Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. Mult Scler 2010; 16:893-896.
251. Brandt AU, Oberwahrenbrock T, Ringelstein M etal. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 2011; 134:e193; author reply e4.
252. Roth NM, Saidha S, Zimmermann H etal. Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis. Eur J Neurol 2013; 20:1170-1176.
253. Kaufhold F, Zimmermann H, Schneider E etal. Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PLOS ONE 2013; 8:e71145.
254. Kaufhold F, Kadas EM, Schmidt C etal. Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT. PLOS ONE 2012; 7:e36965.
255. Naismith RT, Tutlam NT, Xu J etal. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009; 72:1077-1082.
256. Ratchford JN, Quigg ME, Conger A etal. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009; 73:302-308.
257. von Glehn F, Jarius S, Cavalcanti Lira RP, Alves Ferreira MC, von Glehn FH, Costa E, Castro SM, Beltramini GC, Bergo FP, Farias AS, Brandão CO, Wildemann B, Damasceno BP, Cendes F, Santos LM, Yasuda CL. Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders. Mult Scler 2014 Jan 29; epub ahead of print. doi:10.1016/j.jns.2013.01.040.
258. Gelfand JM, Cree BA, Nolan R, Arnow S, Green AJ. Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol 2013; 70:629-633.
259. Sotirchos ES, Saidha S, Byraiah G etal. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology 2013; 80:1406-1414.
260. Schneider E, Zimmermann H, Oberwahrenbrock T etal. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLOS ONE 2013; 8:e66151.
261. Bouyon M, Collongues N, Zephir H etal. Longitudinal follow-up of vision in a neuromyelitis optica cohort. Mult Scler 2013; 19:1320-1322.
262. Ringelstein M, Kleiter I, Ayzenberg I etal. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler 2013 Sep 5; epub ahead of print. doi:10.1177/1352458513503053.
263. Wildemann B, Jarius S, Paul F. [Neuromyelitis optica]. Akt Neurol 2012; 39:33-41.
264. Kimbrough DJ, Fujihara K, Jacob A etal. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012; 1:180-187.
265. Magana SM, Keegan BM, Weinshenker BG etal. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011; 68:870-878.
266. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2013 Nov 29; epub ahead of print. doi:10.1177/1352458513495938.
267. Greenberg BM, Graves D, Remington G etal. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 2012; 18:1022-1026.
268. Pellkofer H, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 2009; 15:1006-1008.
269. Costanzi C, Matiello M, Lucchinetti CF etal. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77:659-666.
270. Watanabe S, Misu T, Miyazawa I etal. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007; 13:968-974.
271. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010; 67:1131-1136.
272. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51:1219-1220.
273. Jacob A, Matiello M, Weinshenker BG etal. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66:1128-1133.
274. Kitley J, Elsone L, George J etal. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013; 84:918-921.
275. Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011; 68:473-479.
276. Weinstock-Guttman B, Ramanathan M, Lincoff N etal. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006; 63:957-963.
277. Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 2013; 84:511-516.
278. Dorr J, Bitsch A, Schmailzl KJ etal. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 2009; 73:991-993.
279. Stroet A, Hemmelmann C, Starck M etal. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord 2012; 5:75-79.
280. Stroet A, Gold R, Chan A. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2012; 78:933; author reply 4.
281. Trebst C, Jarius S, Berthele A etal. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2013; 261:1-16.
282. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012; 78:1179-1185.
283. Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010; 67:1016-1017.
284. Papeix C, Vidal JS, de Seze J etal. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007; 13:256-259.
285. Shimizu Y, Yokoyama K, Misu T etal. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 2008; 255:305-307.
286. Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010; 17:672-676.
287. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007; 252:57-61.
288. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18:113-115.
289. Izaki S, Narukawa S, Kubota A, Mitsui T, Fukaura H, Nomura K. A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment. Rinsho Shinkeigaku 2013; 53:513-517.
290. Qian P, Cross AH, Naismith RT. Lack of response to monoclonal antibody therapy in neuromyelitis optica. Arch Neurol 2011; 68:1207-1209.
291. Miyazaki K, Abe Y, Iwanari H etal. Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4. J Neuroimmunol 2013; 260:107-116.